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Abstract
In acute myocardial infarction patients the injured vascular wall triggers thrombus formation in
the damage site. Fibrin fibers and blood cellular elements are the major components of
thrombus formed in acute occlusion of coronary arteries. It has been established that the initial
thrombus is primarily composed of activated platelets rapidly stabilized by fibrin fibers. This
review highlights the role of platelet membrane phenotype in pathophysiology of myocardial
infarction. Here, we regard platelet phenotype as quantitative and qualitative parameters of the
plasma membrane outer surface, which are crucial for platelet participation in blood
coagulation, development of local inflammation and tissue repair.
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Introduction
Platelets are circulating, small-sized (2-4 mm in diameter) cell
fragments which are the central players in the processes of
hemostasis and thrombosis. They are formed in the bone
marrow by fragmentation of precursor cells (megakaryocytes)
(Italiano & Shivdasani, 2003). One megakaryocyte gives rise
to about 10 000 platelets. The lifespan of circulating platelets
is five to nine days. They are destroyed by the reticuloendo-
thelial cells of the spleen and liver.
In vascular wall injury, e.g. endothelial denudation result-
ing from intravascular intervention or unstable atherosclerotic
plaque rupture, platelets are recruited from the circulation to
the subendothelial matrix forming a hemostatic plug. Platelet
immobilization in the vascular injury is determined by the
specific platelet-vascular wall (adhesion) and platelet-platelet
(aggregation) interactions (Figure 1). Platelets are cellular
elements that among other peripheral blood components are
the first to interact with injured vascular wall. Platelet
adhesion is mediated by glycoprotein (GP) Ib-IX-V receptor-
complex and collagen receptors, GP VI and alpha(2)beta(1)
integrin, located on the platelet surface, and vascular wall
collagen and von Willebrand factor (vWF) (Clemetson &
Clemetson, 2013). Adhesion to the subendothelial extracel-
lular matrix has been regarded as a trigger of platelet
activation, which ultimately leads to the conformational
change of integrins expressed on cellular surface (Figure 2).
Activated platelets form sites for subsequent accumulation of
circulating platelets and leukocytes in the injured vessel wall
(Massberg et al., 2004). Release or production of soluble
agonists (ADP, thrombin, TxA(2), platelet-activating factor,
serotonin, etc.) enhances platelet activation and promotes
further accumulation of cells in the injury. Activated platelets
not only participate in thrombus formation, but also initiate
and/or accelerate inflammatory processes in the vascular wall
(Lindemann et al., 2007).
Intact platelets do not show procoagulant phospholipids on
their surface. These phospholipids are located on the inner
plasma membrane surface and become available by a
mechanism specific for activated platelets. Hemker et al.
(1983) call this process membrane flip-flop (Figure 3).
Membrane flip-flop translocates procoagulant phospholipids
(mainly phosphatidylserine) in the intact platelet from inside
to outside in the activated platelet. Thus, the intact platelet
becomes procoagulant. Clotting factors bind to the procoagu-
lant lipids to form factor X converting enzyme and
prothrombinase.
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Over the past years, it has become clear that platelets are
important not only in thrombosis, but also in inflammation. It
is widely established that platelets are specialized cells of
innate immune defence, modulators of the inflammatory
response, and are involved in wound healing. Beyond the
obvious functions in hemostasis and thrombosis, platelets are
considered to be essential in atherosclerosis, allergy, rheuma-
toid arthritis and cancer. Moreover, platelets are known to
function in innate host defence through the release of
antimicrobial peptides and the expression of pattern recogni-
tion receptors (Gawaz et al., 2005; Gupalo et al., 2013;
Labelle et al., 2011; Lievens & Hundelshausen, 2011).
In atherosclerosis, platelets facilitate the recruitment of
inflammatory cells towards the lesion sites. They do so by
interacting with circulating leukocytes (lymphocytes,
monocytes, neutrophils) and progenitor cells (Figure 4).
This cross-talk enforces leukocyte adhesion, activation and
transmigration. Formation and emergence of platelet-
leukocyte aggregates in the circulation are a manifestation
of enhanced cell-to-cell interactions (Satoh et al., 2004).
Emergence of platelet-leukocyte aggregates facilitates the
development of acute inflammation via stimulation of rolling
and subsequent recruitment of leukocytes into the vascular
wall. By expressing surface cell adhesion proteins (predom-
inantly, P-selectin) platelets support tethering and rolling of
leukocytes in the lesion site. This interaction reduces the flow
rate of leukocytes and ensures their firm adhesion with
subsequent migration into the vascular wall (Bernardo et al.,
2005). High blood level of osteonectin-positive nucleated
cells with QD41 positivity could be regarded as an independ-
ent indicator of stenosing atherosclerotic lesions (Gabbasov
et al., 2007). High content of platelet-leukocyte complexes in
the peripheral blood of patients with coronary heart disease is
an important component of systemic inflammation.
Formation of these aggregates is one of the pathways by
which platelets induce inflammation in the vascular wall,
which may contribute to the development of atherosclerotic
lesions and atherothrombosis (Nijm et al., 2005). In addition,
in acute coronary syndromes platelet-leukocyte aggregates
appear in the bloodstream much earlier than changes in the
standard parameters of platelet activation/activity or in
routine markers of myocardial necrosis, such as CK-MB or
troponin (Furman et al., 2001).
Platelet ability to regulate the homing of precursor cells in
a tissue damage site represents another aspect of platelet
involvement in restoration of injured vascular wall. It was
widely believed that endothelial and smooth muscle cells of a
forming vascular wall, including neointima, arise from
adjacent cells that migrate and proliferate into the lesion
site. However, it was later demonstrated that bone marrow-
derived progenitor cells participate in remodeling and restor-
ation of injured vascular wall (Jiang et al., 2004). Targeted
migration of progenitor stem cells into damaged tissue is an
important stage in the organism’s reaction to damage.
Figure 1. Platelet function in thrombosis. Platelets possess the unique ability to interact with the subendothelial matrix components in areas of injured
vascular wall showed in the upper part. Below, the magnification of the process. Specifically, upon activation, platelets display a number of surface
receptors that enable them to adhere to collagen fibers and von Willebrand factor, other than to recruit further platelets mainly through the integrin
a2b3-fibrinogen cognate interaction and the participation of the mCRP isoform (for comments see the text). In the box on the upper right side, the
symbol explanation is given. mCRP: monomeric isoform C-reactive protein; pCRP: pentameric isoform C-reactive protein; GP: glycoprotein; vWF:
von Willebrand factor.
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The ability of stem cells to migrate into the ‘‘home’’ organ or
injury site is determined by specific biochemical signals sent
from the ‘‘necessary’’ area (Lapidot & Petit, 2002). Stromal
cell-derived factor-1 (SDF-1) is produced by bone marrow
stromal cells and ‘‘retains’’ them in their stem niche.
Activated platelets express and secrete SDF-1, which creates
the initial gradient of this chemokine in the lesion site and is a
major mechanism underlying homing of bone marrow-
derived progenitors at lesion sites, e.g. formation of a mural
thrombus (Massberg et al., 2006). Thus, platelets actively
contribute to formation of niches for homing with subsequent
targeted differentiation of progenitor stem cells. Platelets not
only participate in thrombotic reaction and inflammatory
processes in the vascular wall, but they are also involved
in its regeneration (Daub et al., 2006; Langer et al., 2006;
Stellos et al., 2009). Jankowski et al. (2001) described the
growth-stimulating effect of diadenosine diphosphate (Ap2A),
adenosine guanosine diphosphate (Ap2G) and diguanosine
diphosphate (Gp2G) in releasable granules of human platelets
on cultured vascular smooth muscle cells.
Figure 2. Signal transduction mechanisms upon platelet activation. The binding of GPVI with extracellular collagen fibrils results in clustering and
tyrosine phosphorylation of the FcRg by the Src-family kinases Lyn and Fyn. This leads to activation of the tyrosine kinase Syk through its
phosphorylation which, in turn, causes the tyrosine phosphorylation also of LAT. This latter triggers the assembly of signalling proteins, such as PI3K,
thus leading to the generation of PIP3, and activation of PLCgamma2. As consequence, the IP3 is produced with the end result of mobilization of
calcium from intracellular stores and activation of the integrins expressed on cellular surface. Also the binding of vWF to the GPIb-V-IX complex
finally results in an intracellular calcium overload leading to the upregulation of integrin a2 affinity. However, this specific signalling pathway has not
been completely understood (Zernecke et al., 2005). FcRg: Fc receptor gamma-chain; GP: glycoprotein; IP: inositol (1,4,5)-trisphosphate; LAT:
transmembrane adaptor protein; PIP3: phosphatidylinositol (3,4,5)-trisphosphate; PI3K: Phosphoinositide 3-kinase; PLC: phospholipase Cg2; vWF:
von Willebrand factor.
Figure 3. Membrane flip-flop mechanism. Platelet activation allows the translocation of molecules located in the inner surface of the double layer
cellular membrane to the outer surface, together with the negatively charged phospholipids. Moreover, the a-granules become incorporated in the
plasma membrane, thus allowing both membrane-bound proteins to be expressed on the platelet surface and soluble proteins to be released into the
extracellular space (for comments see the text). In the box on the upper right side, the symbol explanation is given. GP: glycoprotein; SDF: Stromal
cell-derived factor.
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Platelet phenotype
Here we regard platelet phenotype as quantitative and
qualitative parameters of the plasma membrane surface
(membrane phenotype), which are crucial for platelet partici-
pation in blood coagulation, immune reactions and tissue
repair after damage. The modification variability of platelet
membrane phenotype, which is determined by deviations
from native (non-activated) forms (Figure 3), has some
specific features. In contrast to the majority of other cell
types, nucleus-free platelets cannot adapt to environmental
changes by producing their own proteins. However, there is
evidence of residual protein synthesis via megakaryocytic
mRNA (Denis et al., 2005). With preserved parental mRNA,
platelets possess the translational machinery needed for
protein synthesis. Protein production varies in response to
activation, and the proteins are capable of modifying the
phenotype and functional activity of platelets (Thon &
Devine, 2007; Weyrich et al., 2009).
Platelet membrane phenotype is determined primarily by
transmembrane receptors, whose number and state are
fundamental for platelet function (Figure 3). These receptors
include integrins (aIIbb3, a2b1, a5b1, a6b1, aVb3), leucine-
rich repeated (LRR) receptors (Glycoprotein Ib-IX-V, Toll-
like receptors), G-protein coupled transmembrane receptors
(PAR-1 and PAR-4 thrombin receptors, P2Y1 and P2Y12
ADP receptors, TPa and TPb TxA2 receptors), proteins
belonging to the immunoglobulin superfamily (Glycoprotein
VI, FccRIIA), C-type lectin receptors (P-selectin), tyrosine
kinase receptors (thrombopoietin receptor, Gas-6, ephrins and
Eph kinases) and a variety of other types (CD63, CD36,
P-selectin ligand 1, TNF receptor type, etc.). Many of these
receptors have been identified in other cell types; some
receptors, however, are platelet-specific. The receptors are
important for the hemostatic function of platelets, providing
specific interaction and a specific functional response to
vascular wall adhesive proteins and/or soluble humoral
activators. In addition, evidence is being accumulated that
some receptors are involved in less-studied platelet reactions,
for instance, participation in inflammatory and immune
responses, tumor growth, and metastasis of tumor cells
(Clemetson & Clemetson, 2013; Goubran et al., 2013).
Glycoprotein IIb-IIIa complex (integrin aIIbb3) is the best
studied platelet receptor. The aIIbb3 is the only integrin
expressed uniquely on platelets and is the major platelet
integrin (and receptor) with 50 000 to 80 000 copies per
platelet. This protein is always present on platelet plasma
membrane. During activation its conformation changes,
which can be documented with the use of monoclonal
antibodies recognizing the activated or ligand-occupied form
of the receptor. Glycoprotein Ib-IX-V complex, with approxi-
mately 50 000 copies per platelet, is another most common
platelet receptor (after integrin aIIbb3). GPIb-IX-V is a
receptor complex that is always present on the platelet plasma
membrane and is responsible for interaction with vWF
(Clemetson & Clemetson, 2013). Glycoprotein VI (GPVI) is
a member of the immunoglobulin superfamily, expressed
exclusively on platelets and megakaryocytes. It serves as the
major signaling receptor for collagen, which leads to activa-
tion of aIIbb3 integrin and thrombus formation (Nieswandt
et al., 2001). GPVI-mediated collagen responses are receptor
density-dependent at the receptor levels expressed on human
platelets. There appear to be approximately 3000 copies of
GPVI per platelet, and the reduction in the expressed
molecule number down to 500 is associated with a loss of
responsiveness to collagen and a mild bleeding phenotype
(Chen et al., 2002; Dumont et al., 2009). In flow adhesion
experiments that closely approximate physiological condi-
tions, GPVI is essential for the formation of large platelet
aggregates on collagen. However, GPVI-deficient patients or
Figure 4. Platelet function in inflammation. Platelets have been shown to take part in both innate and adaptive immune responses by facilitating the
recruitment of inflammatory cells, including T cells, monocytes and neutrophils, towards the lesion sites. They do so by expressing surface cell
adhesion proteins (predominantly, P-selectin and integrin aIIb3) that address the leukocyte homing and incorporation into atherosclerotic plaques.
Moreover, platelet action also depends on the production of soluble factors, such as growth factors, chemokines, proteases and by releasing
microparticles (for comments see the text). In the box on the upper right side, the symbol explanation is given. PSGL: P-selectin glycoprotein ligand.
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mice do not show any severe bleeding tendency. This suggests
that a GPVI inhibitor can inhibit thrombus formation, but is
not the cause of a significant bleeding tendency (Jung &
Moroi, 2008).
The content of a-granules includes both membrane-bound
proteins that become expressed on the platelet surface and
soluble proteins that are released into the extracellular space
(Figure 3). Most membrane-bound proteins are also present on
the resting plasma membrane. These proteins include some
integrins, immunoglobulin family receptors, leucine-rich
repeat family receptors, tetraspanins and other receptors
(Berger et al., 1993; Maynard et al., 2007; Niiya et al.,
1987; Nurden et al., 2004; Suzuki et al., 2003). However, not
all membrane-bound proteins of a-granules are present on non-
activated platelets (e.g. the stromal cell-derived factor 1a,
P-selectin, CD107a, CD109) (Massberg et al., 2006; Maynard
et al., 2007). Some proteins located only in the intracellular
granules of resting platelets (e.g. P-selectin) emerge on their
surface upon activation. Thus, the presence of P-selectin and
other granular membrane proteins on the platelet surface is an
indicator of platelet activation.
Recent studies show that cells can compensate their limited
abilities to produce specific proteins by receiving them via
uptake of circulating microparticles (microvesicles) produced
by other cell types (Angelillo-Scherrer, 2012; Owens &
Mackman, 2011). Circulating microparticles (MPs) are small
fragments of the plasma membrane which are released upon
activation and/or apoptosis of vascular cells, including
platelets, leukocytes and endothelial cells. The origin of
MPs is revealed by detection of antigenic markers specific for
parental cells. All MPs are procoagulant since on their surface
they contain anionic phospholipids, a substrate for formation
of coagulation complexes. Interaction of leukocyte-derived
MPs with platelets was demonstrated in model experiments
by immune electron microscopy (Rauch et al., 2000) and
flow cytometry (Del Conde et al., 2005; Pluskota et al.,
2008). The exchange of specific proteins via production and
uptake of MPs is an effective tool for coordination of complex
cell reactions, such as atherothrombosis or immune response.
The uptake of MPs produced upon activation of other cell
types enables resting platelets to modify their surface
parameters and membrane phenotype.
Platelet activation is associated with a flip-flop move of
anionic phospholipids from the inner to the outer leaflet,
leading to an increase in these procoagulant phospholipids
from 2 to 12% of the total phospholipid content (Figure 3).
Exposure of anionic phospholipids on the platelet surface can
be monitored by labeling platelets with annexin V, a specific
ligand for amino phospholipids (Do¨rmann et al., 1998).
Exposure of anionic phospholipids on platelets provides a
catalytic surface for procoagulant processes, enabling throm-
bin generation at the site of injury (Sims et al., 1989), and
affects platelet membrane phenotype.
Role of platelet phenotype in pathophysiology
of myocardial infarction
Rapid closure of coronary arteries as a result of occluding
thrombus formation is a major cause of acute coronary
infarction. In patients with acute ST-segment elevation
myocardial infarction (STEMI), fibrin fibers and blood
cellular elements are the major components of thrombus
formed in acute occlusion of coronary arteries; however, the
cellular and fibrin contents of the occlusive thrombus are
highly dependent on ischemia time. Fibrin fibers were the
major component of thrombus, representing more than 60% of
its composition. Platelets, erythrocytes, cholesterol crystals
and leukocytes together comprised the remaining 40%.
‘‘Fresh’’ thrombi have the highest proportion of platelets
(16.8 ± 18%), while the proportion of fibrin fibers increases
over time as the level of thrombin increases, leading to
‘‘older’’ fibrin-rich thrombi (Silvain et al., 2011). The role of
platelet activation in the pathogenesis of the occlusion process
is stressed by a positive correlation between the number of
platelets in a forming thrombus and expression of transmem-
brane glycoprotein CD40, a ligand released by activated
platelets (r¼ 0.40, p¼0.02) (Abu el-Makrem et al., 2009).
These results confirm previous in vivo animal studies showing
the very early stage of thrombus formation, just after
endothelial injury, when the initial thrombus is primarily
composed of activated platelets rapidly stabilized by fibrin
fibers with a decreasing proportion of platelets over time
(Balasubramanian et al., 2002; Shand et al., 1987).
The interaction between platelets and injured vascular wall
triggers platelet accumulation in the damage site. Subsequent
formation of an occluding thrombus strongly depends on the
adhesive properties of platelets and their rapid reaction to
stimuli emerging in the injured vascular wall (Ruggeri, 2002).
These parameters are determined by platelet membrane
phenotype, which can be characterized by transmembrane
receptors responsible for platelet adhesion and activation in
flow. The binding between subendothelial von Willebrand
factor and platelet glycoprotein Ib-V-IX is the initial stage of
interaction that determines transient adhesion of platelets at
the damage site (Savage et al., 1996). Further interaction
between adhesion proteins and glycoprotein IIb-IIIa complex
(aIIbb3) leads to firm adhesion. Massberg et al. (2002)
showed that inhibition of platelet GPIba significantly reduced
both transient and firm adhesion to the vascular surface of the
common carotid artery. In contrast, inhibition of aIIbb3 had
only partial effects on transient platelet adhesion, but almost
completely prevented firm attachment to vascular surface in
vivo. Activation of adhered platelets is determined by
glycoprotein VI (GPVI), another platelet-specific glycopro-
tein whose activity affects the interaction between platelets
and collagen fibrils.
Relationships with the intensity of the corresponding
platelet reactions were demonstrated for GPIIb-IIIa (Sirotkina
et al., 2007), GPI (Baker et al., 2001) and GPVI (Joutsi-
Korhonen et al., 2003) variations. Thus, the amount of
adhesion molecules could be an important indicator of
platelet reactivity. It is established that the number of
adhesion molecules on the platelet surface significantly
varies in normal individuals and cardiovascular patients:
from about two-fold for GPIIb-IIIa and GPIb (Huang et al.,
2003; O’Halloran et al., 2006) to five-fold for GPVI (Furihata
et al., 2001; Joutsi-Korhonen et al., 2003). However, no
differences in GPIIb-IIIa and GPIb numbers on the platelet
surface were detected at days 1, 3–5 and 8–12 after onset of
myocardial infarction, between acute coronary syndrome
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patients and healthy volunteers (Khaspekova et al., 2014).
Another platelet-specific glycoprotein that mediates platelet
adhesion is GPVI. The amount of GPVI is upregulated on
circulating platelets in acute coronary syndrome (Bigalke
et al., 2006), and as a consequence, inhibition of GPVI
decreases atherosclerosis progression in experimental models
(Bu¨ltmann et al., 2010).
Histological examination of occluded coronary arteries of
patients with acute myocardial infarction (MI) shows increased
levels of microparticles (MP) bearing tissue factor (TF).
Elevation of procoagulant TF-positive MPs within the
occluded coronary artery of patients with MI suggests their
pathophysiological role in coronary atherothrombosis (Morel
et al., 2009; Palmerini et al., 2013). Generation of these
microvesicles by activated leukocytes is well established
(Angelillo-Scherrer, 2012; Mallat et al., 2000), while the
mechanism of accumulation by occlusive thrombus in general
is not known. Acquisition could potentially be mediated by
these procoagulant proteins being carried by platelets.
Previously, we evaluated the presence of platelets carrying
leukocyte membrane marker CD45 in acute myocardial
infarction patients. It was found that the fraction of CD45-
positive platelets was significantly higher in patients on the
first day, and increased further on days 8–10 after MI
(Gabbasov et al., 2014). We suggested that platelets gain TF
by binding leukocytic MPs, which was confirmed by in vitro
coincubation of platelets and MPs released from activated
granulocytes.
It has become clear that the prototypic acute phase reactant
C-reactive protein (CRP) is not only a marker but also a
potential active player in the inflammatory process. Being
part of the acute phase reaction, plasma levels increase during
inflammatory response. Recent evidence suggests that CRP
occurs in at least two different conformations: circulating
highly soluble native, pentameric CRP (pCRP) and mono-
meric isoform (mCRP) formed as a result of pCRP dissoci-
ation (Wu et al., 2003), representing rather the tissue-bound
form of CRP. A physiologically relevant mechanism of anti-
inflammatory pCRP dissociation by activated platelets was
identified and deposition of pro-inflammatory mCRP in
inflamed tissue was demonstrated (Eisenhardt et al., 2009).
Molins et al. (2011) have shown that dissociation of blood
circulating pCRP into mCRP occurs on shear-induced
growing thrombus, and the newly formed mCRP induces
further thrombus growth (Figure 1). Furthermore, unlike
pCRP, mCRP induces platelet activation and aggregation.
Detection of pro-inflammatory mCRP microparticles in the
blood of patients following MI confirmed the hypothesis that
dissociation of blood circulating pCRP is catalyzed by
‘‘activated’’ membranes containing lysophospholipids
(Habersberger et al., 2012). These data indicate that mono-
meric C-reactive protein, which dissociates from pentameric
C-reactive protein on the surface of activated platelets, could
contribute to atherothrombotic complications in acute coron-
ary syndrome patients by promoting local inflammation.
The chemokine stromal cell-derived factor-1 (SDF-1) is
released by activated platelets to recruit bone marrow-derived
stem cells at the site of arterial vascular injury, and mediates a
P-selectin- and CXCR4-dependent arrest of progenitor
cells on matrix-adherent platelets (Zernecke et al., 2005).
In experimental studies, the expression of SDF-1 by the
platelet-rich thrombus was shown as early as 30 min after
vascular injury (Massberg et al., 2006). A later clinical trial
has shown significantly enhanced platelet expression of SDF-
1 in patients with acute coronary syndrome compared with
patients with stable angina pectoris (Stellos et al., 2009).
Clinical impact of platelet phenotype in patients
with myocardial infarction
The involvement of platelets in atherothrombotic diseases is
unquestioned and investigation of different platelet functional
activities in coronary artery disease is an important part of
many clinical studies. Several assays are currently available to
measure platelet reactivity, and platelet function testing is a
valuable tool to assess the effectiveness of antiplatelet drugs.
Platelet reactivity testing might become a useful tool to help
balance between bleeding and thrombosis with aggressive
antiplatelet therapy in acute coronary syndrome (Aradi et al.,
2013). High platelet reactivity can be considered a risk factor
for patients with MI. The increased hazard associated with high
platelet reactivity has been demonstrated by various platelet
testing (Franchi et al., 2014). Many researchers attempt to find
an optimal method for monitoring platelet reactivity and a
‘‘therapeutic window’’, which describes an optimal range of
platelet reactivity associated with minimal risk of bleeding and
ischemic complications. However, the majority of platelet
reactivity assays show only a limited correlation between high
platelet activity and ischemic events, and could not predict
adverse cardiac events (Tantry et al., 2013).
Tests exploring platelet functional activity in patients with
acute coronary syndrome, mainly platelet aggregation, are best
clinically validated. Among these tests, the assessment of
platelet membrane phenotype is less investigated.
Nevertheless, new clinical data indicate that expression of
some membrane proteins on the platelet surface may be useful
in clinical practice as early additional biomarkers for cardio-
vascular risk stratification. We will present several new clinical
studies which examined the predictive value of two different
membrane-associated proteins for acute coronary syndromes
to identify patients with a high risk of coronary events.
The first is a prospective study in which the predictive value
of platelet surface GPVI for acute coronary syndromes was
examined in a large consecutive group of patients with
symptomatic coronary artery disease to identify the high-risk
cohort with imminent coronary events. A total of 1003 patients
with symptomatic coronary artery disease were verified by
coronary angiography, and platelet surface expression of GPVI
was determined using flow cytometry. Patients with ACS
(n¼ 485) showed considerably increased PVI expression
compared to patients with stable angina pectoris (n¼ 518).
Logistic regression analysis showed that an elevated platelet
GPVI level can be indicative of ACS independent of myocar-
dial necrosis biomarkers, including troponin, creatine kinase
and creatine kinase-MB. Moreover, patients with increased
platelet activation showed significant enhanced residual
platelet aggregation despite dual antiplatelet therapy compared
to patients with low GPVI levels (Bigalke et al., 2008). In the
second study, 1004 patients with chest pain were consecutively
examined in a prospective design. ACS was found in 416
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(41.4%), stable angina pectoris in 233 (23.2%), and non-
coronary (NC) causes of chest pain in 355 patients (35.4%).
Patients with ACS showed higher GPVI expression compared
to patients with SAP or NC causes of chest pain. Patients with
elevated GPVI expression had a poorer clinical outcome than
patients with baseline GPVI expression in respect of composite
cumulative survival that included myocardial infarction,
stroke, and cardiovascular death at three months (Bigalke
et al., 2010a). Finally, this group of researchers evaluated 2213
consecutive patients suffering from chest pain in a prospective
study. The Kaplan-Meier analysis for cumulative event-free
survival revealed that patients with an elevated baseline GPVI
expression had a poorer clinical outcome for cardiovascular
death than patients with decreased GPVI levels. These results
were paralleled in composite cumulative survival that included
myocardial infarction, stroke and cardiovascular death
(Bigalke et al., 2010b).
Another platelet membrane protein which is included in a
large clinical study is stromal cell-derived factor-1 (SDF-1).
Expression of this protein is enhanced during ischemic events
and may play an important role in trafficking hematopoietic
progenitor cells for tissue regeneration and neovascularization.
In a prospective study, 1000 patients who were admitted to the
emergency department with chest pain were consecutively
evaluated. Platelet surface expression of GPIb and SDF-1 was
determined by flow cytometry. Patients with ACS showed
considerably higher SDF-1 expression on admission compared
to patients with stable angina pectoris and chest pain of other
origins. Logistic regression analysis showed that surface
expression of platelet SDF-1 was significantly associated
with ACS. Areas under the curve of receiver operating
characteristic analysis revealed 0.718 (95% confidence interval
(CI):0.680-0.757) using SDF-1 and 0.795 (95% CI: 0.760-
0.829), applying troponin-I baseline serum levels. Patients
with higher SDF-1 levels had a 1.4-fold relative risk (95% CI:
1.17-1.52) for ACS (Wurster et al., 2013).
These data indicate that determination of platelet GPVI and
SDF-1 can be useful as early additional biomarkers for
cardiovascular risk stratification in patients with acute coron-
ary syndrome. Moreover, GPVI can be helpful to distinguish an
imminent ACS from non-coronary causes in patients with
chest pain who are transferred to a chest pain unit before
myocardial necrosis is evident with classical biomarkers.
Genetic polymorphisms and platelet receptors
Genetic variations in a2b1 integrin were reported to be
associated with the density of a2b1 receptors on the platelet
surface (Kunicki et al., 1997). Namely, an association
between genetic variations in a2b1 and the density of a2b1
receptors on the platelet surface was reported. Kunicki et al.
(1997) demonstrated that the density of a2b1 receptors on the
platelet surface affects platelet adhesion to collagen, con-
tributing to an increased risk of thrombosis.
Both GPIIb and GPIIIa are known to bear a number of
single amino acid substitutions affecting conformational
changes and the ligand binding function with little or no
effect on platelet function. A platelet-specific antigen (PlA1/
A2) polymorphism has been by far the most investigated
GPIIIa gene polymorphism. A substitution of cytosine for
thymidine at position 1565 in exon 2 of the GPIIIa gene leads
to an amino acid difference at position 33: a leucine (A1
allele) or a proline (A2 allele) (Kozieradzka et al., 2007). The
above-mentioned polymorphism can influence both platelet
activation and aggregation and affect post-occupancy signal-
ing by the platelet fibrinogen receptor IIb/IIIa (Feng et al.,
1999; Vijayan et al., 2003). The presence of one or two PlA2
alleles is associated with an increased binding affinity to
fibrinogen as well as with platelet aggregability in response to
epinephrine, ADP and collagen in vitro (Michelson et al.,
2000). It has also been suggested that the PlA2 allelic variant
causes increased sensitivity to platelet aggregation by various
agonists and altered sensitivity to aspirin (Bajt et al., 1994;
Cooke et al., 2006; Szczeklik et al., 2000).
Conclusion with perspectives
The platelet is a complex cell packed full of active molecules
and metabolites and is able to rapidly change native phenotype
upon activation. It is well established that increased platelet
activation can contribute to atherothrombosis and inflamma-
tion in patients with acute coronary syndrome. The negative
effect of platelets can be reduced through antiplatelet ther-
apy by inhibiting their pro-thrombotic and pro-inflammatory
properties. These properties are strongly determined by platelet
phenotype, which can be described by surface expression of
different types of membrane-associated proteins. Among these
we can highlight glycoprotein receptors and integrins (GPIb,
GPVI, aIIbb3, a2b1, etc.), procoagulant proteins (lysopho-
spholipids, coagulation factors), cell adhesion molecules
(selectins, fibrinogen, fibronectin, vWF, etc.), chemokines
(SDF-1) and some membrane-associated pro-inflammatory
proteins (mCRP). Membrane-associated proteins that mediate
thrombosis and inflammation might represent hypothetically
ideal markers of their functional status. For example, for ACS
patients remaining on clopidogrel, platelet reactivity testing
seems to be of crucial importance due to the variable and
unpredictable effect of clopidogrel. Platelet phenotype iden-
tification to assess the level of P2Y12-receptor inhibition may
play a key role in choosing the best drug for the individual
patient.
An ideal and reliable platelet activation biomarker should
be cheap, usable away from specialized laboratories, inform-
ative and specific in order to orientate the physician towards
diagnosis or predictable outcome. Moreover, a test for
monitoring antiplatelet drugs should be validated not only
in terms of discriminating patients at risk, but in terms of
demonstrating that alternative treatment regimens are effect-
ive. Unfortunately, unlike myocardial injury markers such as
troponins, and despite the fact that several biomarkers of in
vivo platelet activation have been suggested, none offers ideal
diagnostic properties (Ferroni et al., 2012; Harrison, 2012).
For example, platelet phenotype description requires a
complex, time-consuming sample preparation, the use of a
flow cytometer, and an experienced technician.
Irrespective of differences in the determination of mem-
brane-bound proteins whose levels are strongly associated
with disease diagnosis, therapy and prognosis, these deter-
minations are possible, albeit on a limited scale. Today,
platelet phenotyping can be used for better diagnosis or in
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combination with reflection of distinct pathophysiological
features of ACS, such as cell necrosis, vascular inflammation
or oxidative stress that significantly improve our ability to
identify patients who are at risk of adverse cardiovascular
events (De Filippi & Seliger, 2009). Large-scale implemen-
tation of these technologies requires simple and informative
methods for point-of-care testing that allows cell activity
monitoring without highly qualified personnel. This will need
to be validated by extensive clinical trials. Nevertheless, there
are experimental prerequisites for these methods.
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